KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-Current Deffered Revenue (2016 - 2025)

CRISPR Therapeutics AG's Non-Current Deffered Revenue history spans 11 years, with the latest figure at $12.3 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $12.3 million; the TTM value through Sep 2025 reached $12.3 million, changed 0.0%, while the annual FY2024 figure was $12.3 million, 12.05% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $12.3 million at CRISPR Therapeutics AG, roughly flat from $12.3 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $15.8 million in Q3 2023 and bottomed at $11.8 million in Q2 2021.
  • The 5-year median for Non-Current Deffered Revenue is $12.3 million (2021), against an average of $12.6 million.
  • The largest annual shift saw Non-Current Deffered Revenue grew 28.4% in 2023 before it decreased 22.12% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $12.3 million in 2021, then changed by 0.0% to $12.3 million in 2022, then grew by 13.71% to $14.0 million in 2023, then decreased by 12.05% to $12.3 million in 2024, then changed by 0.0% to $12.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Non-Current Deffered Revenue are $12.3 million (Q3 2025), $12.3 million (Q2 2025), and $12.3 million (Q1 2025).